
Phase 3 OptIMMize-1 findings show sustained skin clearance, itch reduction, and quality-of-life improvements with risankizumab through 52 weeks.
To examine whether glutathione is a major antioxidant in melanocytes, researchers at the Norwegian Radium Hospital, Oslo, Norway, depleted melanocytes of glutathione via buthionine sulfoximine.